Endo International’s subsidiary, Par Sterile Products, has entered an agreement to expand its sterile fill-finish manufacturing production capacity and capabilities at its Rochester, MI plant to support the U.S. government’s national defense efforts for the production of critical medicines advancing pandemic preparation.
 
Par Sterile’s Rochester facility will establish a new sterile fill-finish manufacturing asset capable of processing liquid or lyophilized products requiring Biosafety Level (BSL) 2 containment. Par will also provide expanded product inspection and packaging capacity and sterile fill-finish manufacturing services to the U.S. Government. The U.S. government will fund approximately $90 million of the program’s total expected cost of approximately $120 million.
 
“Endo strives to be a force for good, and we are proud to partner with the U.S. government in its efforts to expand and accelerate domestic manufacturing in support of future pandemic preparedness,” said Blaise Coleman, President and CEO of Endo. “This collaboration underscores our longstanding history as a U.S. manufacturer of high-quality medicines.”
 
The agreement is a result of efforts defined under the Defense Production Act to address vulnerabilities in critical product supply chains and strengthen the advancement of manufacturing and on-shoring of domestic essential medicines production.